Serum SCCA–IgM levels at baseline and 1 month after treatment were significantly lower in patients who responded to therapy than in those who did not respond [60], suggesting that SCCA–IgM level determination could help predict the response to therapy in HCC patients. This evidence concerns the gene CD40LG and hepatocellular carcinoma.